SNRIs work by increasing the levels of the neurotransmitters serotonin and norepinephrine in the brain. Serotonin and norepinephrine are naturally occurring chemicals in the brain that play important roles in mood regulation. Low levels of these neurotransmitters have been linked to depression. SNRIs work by blocking the reabsorption (reuptake) of serotonin and norepinephrine back into neurons after they have been released. This allows the neurotransmitters to stay in the synapse longer, improving communication between neurons. Common SNRIs prescribed include duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq).
Effectiveness against depression
Numerous clinical trials have shown SNRIs to be effective for treating major depressive disorder. While selective serotonin reuptake inhibitors (SSRIs) were previously the most commonly prescribed first-line treatment for depression, SNRIs are gaining popularity due to the belief that they may work better for certain types of depression. Studies have found SNRIs to be equally or more effective than SSRIs for conditions like chronic depression, depression associated with anxiety disorders, and depression accompanied by physical symptoms like pain. SNRIs may provide a faster onset of action and higher remission rates than SSRIs in some cases.
Growing use despite higher cost
While SNRIs do not have generic versions available yet in the US, insurance coverage and use has significantly expanded in recent years. SNRIs are often more expensive than generic SSRIs and may cost two to four times as much for a month's supply. However, this higher upfront cost is outweighed for insurers if the person achieves remission faster and avoids more expensive care down the line, such as additional medications, therapy, or hospitalization. As a result, many insurance plans have placed SNRIs on lower cost-sharing tiers to encourage their use over SSRIs when clinically appropriate. As patents on branded SNRIs expire in the next few years, the availability of lower-cost generics may push use of these drugs even higher.
Expanded indications beyond depression
Originally developed and approved for the treatment of major depressive disorder, SNRIs are now routinely prescribed for other conditions due to their dual action on serotonin and norepinephrine. Some common "off-label" uses of SNRIs include:
- Generalized anxiety disorder: SNRIs can reduce physiological symptoms like chronic muscle tension as well as excessive worries.
- Social anxiety disorder: SNRIs may improve symptoms of anxiety experienced in social situations and performance venues.
- Panic disorder: SNRIs are a first-line treatment option for reducing panic attacks and anticipatory anxiety.
- Chronic pain conditions: The pain-relieving effects of SNRIs have made them a standard treatment for fibromyalgia, diabetic neuropathy, arthritis, and other forms of chronic musculoskeletal pain.
- PTSD: SNRIs can lessen core symptoms of post-traumatic stress disorder like flashbacks, nightmares, and hyperarousal.
- Menopausal symptoms: SNRIs are commonly prescribed off-label for hot flashes, mood swings, and other vasomotor symptoms of menopause.
Side effects are treatment-limiting for some
While generally well-tolerated, serotonin norepinephrine inhibitors do commonly cause mild to moderate side effects, at least initially, in many people. Common adverse events reported include nausea, headache, insomnia, drowsiness, fatigue, sexual dysfunction, and constipation or diarrhea. For some individuals, side effects may be severe enough to warrant changing medications or discontinuing treatment altogether. SNRIs also carry boxed warnings for potential increased suicidal thoughts in children, adolescents, and young adults. Careful symptom monitoring during the first few months of treatment is recommended. However, for many patients the benefits of SNRIs outweigh these potential risks.
Role in stepped care models
Given their increasing effectiveness data and expanding indications, serotonin norepinephrine inhibitors are playing a prominent role in stepped care models for treating psychiatric conditions. In stepped care models, medications like SNRIs that provide the highest benefit-risk balance are tried before progressing to less tolerated or more expensive therapies. This allows maximum chances for remission using front-line options before resorting to augmentation, combination therapies, or moving to newer branded drugs. SNRIs serve as a bridge between generic SSRIs and newer treatments, including vilazodone (Viibryd) and vortioxetine (Trintellix), two more recent entrants to the antidepressant drug market. With expected SNRIs generics in the coming years, this drug class will likely remain the standard first-line pharmacological treatment option for mood and anxiety disorders for the foreseeable future.
In conclusion, SNRIs have emerged as one of the leading classes of antidepressant medications due to their tolerability, effectiveness against a range of depressive and anxious symptom profiles, cost-effectiveness, and wide range of approved and off-label uses. As patent expirations lead to lower-cost generics, and with expanding evidence for their benefits, SNRIs are poised to become even more prominent front-line pharmacologic treatments for psychiatric conditions.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
